|
|
|
Volumn 26, Issue 5 SUPPL. 14, 1999, Pages 66-73
|
|
Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
a
a
BIOGEN
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2A INTERFERON;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
INTERFERON;
PREDNISONE;
RITUXIMAB;
VINCRISTINE;
ADVERSE DRUG REACTION;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
COMPLEMENT DEPENDENT CYTOTOXICITY;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
NONHODGKIN LYMPHOMA;
PRIORITY JOURNAL;
RADIOIMMUNOTHERAPY;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD20;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL RESPONSE MODIFIERS;
CLINICAL TRIALS, PHASE II;
HUMANS;
LYMPHOMA, B-CELL;
RADIOIMMUNOTHERAPY;
REMISSION INDUCTION;
YTTRIUM RADIOISOTOPES;
|
|
EID: 0032740187
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (297)
|
|
References (18)
|
